Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Aimmune Therapeutics, Inc.

Aimmune Therapeutics to Present New Data for PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] at the EAACI Hybrid Congress 2022
From Aimmune Therapeutics, Inc.
Via Business Wire
Aimmune Therapeutics Announces Publication of Pooled Safety Analysis of PALFORZIA® Treatment for up to 2 Years in the Journal of Allergy and Clinical Immunology
From Aimmune Therapeutics, Inc.
Via Business Wire
Aimmune Therapeutics Presents New PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder-dnfp] Data on Immunological Outcomes of Long-Term Daily Oral Immunotherapy at the EAACI PAAM Digital Meeting
From Aimmune Therapeutics, Inc.
Via Business Wire
Aimmune Therapeutics to Present New Data at ACAAI on the Real-World Burden of Peanut Allergy and Early Physician Experience with PALFORZIA® in Clinical Practice in the U.S.
From Aimmune Therapeutics, Inc.
Via Business Wire
Aimmune’s PALISADE-ARC004 Longitudinal Study Showed PALFORZIA® Safety and Efficacy Increased Over Time in Patients with Peanut Allergy
From Aimmune Therapeutics, Inc.
Via Business Wire
Aimmune Launches the First Real-World Registry Study for Patients with Chronic Pancreatitis
From Aimmune Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.